BioSpace News Archive

Araim Pharmaceuticals, Inc. is pleased to announce the appointment of Ferdinand “Ferry” Breedveld, MD, PhD, the Chairman of the Board at Araim, as the organization’s acting Chief Executive Officer.

New preclinical data using a humanized mouse model confirms and expands on the potential use of leronlimab in treating this inflammatory syndrome, a common precursor to NASH

Vizient announced it has signed an agreement with Fresenius Kabi to supply six critical care drugs under Vizient’s successful Novaplus private label pharmacy program.

FAIR Health has won six eHealthcare Leadership Awards for 2019, as announced on November 6 at the Healthcare Internet Conference, sponsored by Greystone.Net, in Orlando, Florida.

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis.

Abacus Health Products, Inc. (CSE: ABCS, OTCQX:ABAHF) (“Abacus” or the “Company”) today announced that it has received a purchase order from an additional major national pharmacy chain in the United States, which will be offering products from its CBDMEDIC product line

Rockwell Medical, Inc. announced that Stuart Paul, Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference

Entera Bio Ltd. announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the Company’s future financing efforts to support the company’s growth initiatives..

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that Japan’s Ministry of Health, Labour and Welfare has approved the BRACAnalysis® Diagnostic System to help physicians determine which women with breast cancer have Hereditary Breast and Ovarian Cancer syndrome and qualify for additional medical management.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced that it received Orphan Drug designation from the Food and Drug Administration for QR-1123.